Mounjaro vs. Zepbound: same drug, same dose ceiling, different label
Unlike Ozempic and Wegovy, Mounjaro and Zepbound share the exact same maximum dose. The real differences are what each is FDA-approved for, and which patient population the trial results reflect.
Same titration schedule, same ceiling
Both drugs follow the identical FDA titration schedule: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, stepping up roughly every four weeks.
Approved for type 2 diabetes. Weight loss is a documented secondary effect, most robustly shown in the SURMOUNT-2 trial (adults with type 2 diabetes).
Approved for chronic weight management and, since December 2024, obstructive sleep apnea in adults with obesity.
Side by side
| Mounjaro | Zepbound | |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| FDA approved for | Type 2 diabetes | Chronic weight management; obstructive sleep apnea (Dec 2024) |
| First approved | May 2022 | November 2023 |
| Maximum weekly dose | 15 mg | 15 mg |
| Formats | Multi-dose injection pen | Single-dose pen; vials (cash-pay via LillyDirect) |
| Weight loss in trials | ~13–16% over 72 wks (SURMOUNT-2, patients with diabetes) | ~16–21% over 72 wks (SURMOUNT-1, patients without diabetes) |
| Insurance coverage | Often covered for a diabetes diagnosis | Varies; frequently requires prior authorization |
| List price without insurance | ~$1,080–1,112/mo | ~$1,086/mo (pens); $349–499/mo (vials, cash-pay) |
The weight-loss percentages above aren't a head-to-head trial — they come from two different SURMOUNT studies with different patient populations. People with type 2 diabetes (the Mounjaro-relevant population) tend to lose somewhat less weight on GLP-1 therapy than people without diabetes, independent of which drug they're on.
Which one fits your situation
Mounjaro tends to make sense if
- You have a type 2 diabetes diagnosis
- Blood sugar control is the primary goal, with weight loss as a secondary benefit
- Your insurance covers GLP-1/GIP therapy for diabetes but not for weight loss alone
Zepbound tends to make sense if
- Weight loss is your primary goal, without a diabetes diagnosis
- You have obstructive sleep apnea alongside obesity — the only tirzepatide product with that specific approval
- You want access to the cash-pay vial option through LillyDirect, which is meaningfully cheaper than either brand's pen list price
On cost: Zepbound's vial format, sold directly through LillyDirect, is the cheapest legitimate path to tirzepatide for most uninsured patients — well under either brand's pen list price. Mounjaro has no equivalent direct cash-pay program.
Common questions
Can a doctor prescribe Mounjaro for weight loss instead of Zepbound?
Off-label prescribing does happen, but without a diabetes diagnosis it's less likely to be covered by insurance, and Zepbound is the version specifically studied and labeled for weight management — including the sleep apnea indication Mounjaro doesn't carry.
Do Mounjaro and Zepbound have the same side effects?
Since they're the same active ingredient at the same doses, the side effect profile is essentially identical — nausea, diarrhea, and other GI symptoms are most common, tend to track with dose, and typically ease as your body adjusts to a given dose over a few weeks.
Why does Zepbound have a sleep apnea approval and Mounjaro doesn't?
The FDA approves a drug for the specific condition and population studied in its clinical trials. Zepbound's sleep apnea approval, granted in December 2024, was based on trials specifically in adults with obesity and obstructive sleep apnea — a population and endpoint Mounjaro's diabetes trials didn't study.
Is tirzepatide (Mounjaro/Zepbound) more effective than semaglutide (Ozempic/Wegovy)?
A head-to-head trial (SURMOUNT-5) found tirzepatide produced greater average weight loss than semaglutide at each drug's highest studied weight-loss dose. That's a population-level result, though — individual response varies, and the right choice depends on more than one trial's average outcome.
See current pricing from telehealth providers
Ro, Found, and Sequence each structure pricing differently for tirzepatide access. Pricing on this page reflects list and cash-pay figures and can differ from what a provider quotes.
Medical disclaimer: This page is for general information and isn't a substitute for professional medical advice. Talk to a licensed healthcare provider before starting, stopping, or switching any medication.
Advertising disclosure: DosageBuzz has affiliate partnerships with some telehealth providers linked on this page. We may earn a commission if you sign up through these links, at no additional cost to you.